Cover Image

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report

Yuanping Chen,1 Chao Liu,1 Xinglin Wen,2 Chen Wang,1 Jing He1 1Department of Oncology, Ganzhou People's Hospital, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, People's Republic of China; 2Department of Medical Image, Ganzhou People's Hospital, The Affiliated Ganzho...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chen Y (Author), Liu C (Author), Wen X (Author), Wang C (Author), He J (Author)
Format:	Book
Published:	Dove Medical Press, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022)

Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023)

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
by: Peter G. Rose
Published: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
by: Mei Zhan, et al.
Published: (2023)

Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases
by: Qiongwen Zhang, et al.
Published: (2024)

Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022)

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
by: Christina Vasalou, et al.
Published: (2024)

Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia
by: N. A. Avxentyev, et al.
Published: (2024)

Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases
by: Wang C, et al.
Published: (2024)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
by: Blair McNamara, et al.
Published: (2023)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi S, et al.
Published: (2014)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
by: Iago Dilion Lima Cavalcanti, et al.

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021)

Calcium Electroporation for Management of Cutaneous Metastases in HER2-Positive Breast Cancer: A Case Report
by: Katrine Borres Jensen, et al.
Published: (2022)

Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis
by: Marta Sevieri, et al.
Published: (2023)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
by: Yiwen You, et al.
Published: (2018)

Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells
by: Shaghayegh Saharkhiz, et al.
Published: (2024)

Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
by: Taha Koray Sahin, et al.
Published: (2024)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
by: SPH Mao, et al.
Published: (2023)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
by: Ratnakar Reddy Kuchukulla, et al.
Published: (2022)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
by: Huifang Lv, et al.
Published: (2023)

Trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib for the targeted therapy of HER-2-positive breast cancer
by: Xing Liu, et al.
Published: (2024)

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
by: Moslem Afrakhteh, et al.
Published: (2017)

Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
by: Elena M. Tosca, et al.
Published: (2023)

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
by: Sudewi Mukaromah Khoirunnisa, et al.
Published: (2023)

In Vitro Assessment of <sup>177</sup>Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
by: Ayça Tunçel, et al.
Published: (2024)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014)

The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients
by: Jia-qi Yuan, et al.
Published: (2020)

Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC
by: Feifei Li, et al.
Published: (2024)